1 Department of Internal Medicine, National Cancer Center Hospital, Tokyo; 2 Division of Thoracic Oncology, National Cancer Center Hospital, Kashiwa City; 3 Division of Respiratory Medicine, Yokohama Municipal Citizens Hospital, Yokohama; 4 Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
Received 20 April 2003; revised 17 August 2003; accepted 28 August 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
To evaluate the efficacy and safety of treatments for advanced non-small-cell lung cancer in elderly patients aged 75 years or older, we conducted a phase II study of cisplatin and docetaxel administered in three consecutive weekly infusions.
Patients and methods:
The eligibility criteria for the study included the presence of chemotherapy-naive advanced non-small-cell lung cancer, age 75 years, Eastern Cooperative Oncology Group performance status of 0 or 1, a measurable lesion, adequate organ functions and signed informed consent. The chemotherapy regimen consisted of cisplatin (25 mg/m2) and docetaxel (20 mg/m2) on days 1, 8 and 15 every 4 weeks.
Results:
Between February 2000 and March 2002, 34 elderly patients with non-small-cell lung cancer were enrolled in the study and 33 patients were treated. Two complete responses and 15 partial responses were obtained for an objective response rate of 52% in 33 treated patients. The median survival period was 15.8 months, and the 1-year survival rate was 64%. Toxicities were mild with no grade 4 toxicities. Only grade 3 leukopenia (6%), neutropenia (12%), anemia (3%), hyponatremia (3%) and nausea/vomiting (3%) were observed.
Conclusion:
Cisplatin and docetaxel administered in three consecutive weekly infusions was safe and effective for the treatment of elderly patients with chemotherapy-naive non-small-cell lung cancer.
Key words: cisplatin, docetaxel, elderly patients, non-small-cell lung cancer, weekly administration
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Docetaxel has demonstrated antitumor activity in NSCLC patients with chemotherapy-naive lesions and tumor progression after receiving cisplatin-based regimens [610]. Docetaxel with cisplatin is one of the most promising chemotherapy regimens for NSCLC [11]. The commonly used dose and schedule of docetaxel is 60100 mg/m2 every 3 weeks; however, moderate to severe neutropenia is frequently observed [611]. Recent studies have shown that weekly administration of docetaxel produces a higher dose intensity and less myelotoxicity [1214]. Thus, we conducted two independent phase I studies for elderly and non-elderly patients with NSCLC to determine the recommended dose for phase II studies and to evaluate the safety and efficacy of cisplatin and docetaxel administered as three consecutive weekly infusions in both non-elderly (74 years) and elderly (
75 years) patients [15]. Different recommended doses of docetaxel were obtained for non-elderly and elderly patients [15]. The recommended doses were 25 mg/m2 cisplatin and 35 mg/m2 docetaxel on days 1, 8 and 15 for non-elderly patients, and 25 mg/m2 cisplatin and 20 mg/m2 docetaxel on days 1, 8 and 15 for elderly patients.
Two phase II studies of cisplatin and docetaxel administered as three consecutive weekly infusions for non-elderly and elderly patients were conducted. The results of the phase II study for non-elderly patients with NSCLC have been reported elsewhere; the objective tumor response was 30% [95% confidence interval (CI) 15% to 46%] and the median survival time was 12.8 months [16]. Here, we report the promising results of a phase II study for elderly patients with NSCLC.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Patient evaluation
The pretreatment evaluation consisted of complete blood cell count, differential count, routine chemistry measurements, a chest radiograph, a chest computed tomography (CT) scan, abdominal ultrasound or CT scan, whole-brain magnetic resonance imaging or CT scan, and an isotope bone scan. Complete blood cell count, differential, count and routine chemistry measurements were carried out at least twice a week during the first course of chemotherapy.
Treatment schedule
All patients were admitted to hospital during the first course of chemotherapy. Chemotherapy consisted of cisplatin (25 mg/m2) on days 1, 8 and 15 and docetaxel (20 mg/m2) on days 1, 8 and 15 every 4 weeks. Docetaxel was infused over 30 min with 16 mg dexamethasone and 3 mg granisetron administered just before the docetaxel infusion. Ninety minutes after the completion of the docetaxel infusion, 25 mg/m2 cisplatin were administered over 15 min with 1500 ml normal saline over 3.5 h. The prophylactic administration of G-CSF was not permitted. Administration of G-CSF was permitted in patients with grade 4 neutropenia and/or leukopenia or grade 3 febrile neutropenia. The administration of both cisplatin and docetaxel were skipped on day 8 and/or day 15 if the patients met the following criteria: WBC <2000/mm3 and/or platelets <50 000/mm3. No dose modifications were carried out on days 8 and/or day 15 of the cisplatin and docetaxel administrations. Treatment was carried out for at least two courses, unless unacceptable toxicity or disease progression occurred.
Response and toxicity evaluation
The patients responses were evaluated according to the World Health Organization criteria [17]. A complete response (CR) was defined as the complete disappearance of all clinically detectable tumors for at least 4 weeks. A partial response (PR) was defined as a reduction of 50% in the product of the largest perpendicular diameters of one or more clearly measurable lesions or as a >50% reduction in evaluable malignant disease lasting for >4 weeks with no new areas of malignant disease. No change included: the regression of indicator lesions that were insufficient to meet the criteria for PR, <25% increase in any measurable lesion and no new lesions of malignant disease. Progressive disease was defined as an increase in any measurable lesion by >25% or a new lesion of malignant disease. Survival times from the start of treatment were calculated using the KaplanMeier method. The toxicity grading criteria of the Japan Clinical Oncology Group (JCOG) were used to evaluate toxicity [18]. Most detailed gradings for individual organ toxicity in the JCOG Toxicity Criteria are identical to those of the National Cancer Institute Common Toxicity Criteria proposed in 1988. The only differences in the definitions used in the present study were that neutrophils were used instead of granulocytes and the definitions for nausea and vomiting were combined.
Statistical analysis
According to the minimax two-stage phase II study design by Simon [19], the treatment program was designed to refuse response rates of 20% and to provide a significance level of 0.05 with a statistical power of 80% in assessing the activity of the regimen as a 40% response rate. The upper limit for first-stage drug rejection was four responses among 18 evaluable patients; the upper limit of second-stage rejection was 10 responses among 33 evaluable patients. Overall survival was defined as the interval between enrolment in this study and death or the last follow-up visit. Median overall survival was estimated using the KaplanMeier analysis method [20].
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
Objective tumor response and overall survival
The objective tumor response is shown in Table 3. Two CRs and 15 PRs occurred for an objective response rate of 52% (95% CI 31% to 67%) in 33 treated patients. The overall survival periods of all treated patients are shown in Figure 1. The median survival time of the 33 treated patients was 15.8 months with a median follow-up time for 11 censored patients of 18.1 (15.235.5) months. The 1-year and 2-year survival rates were 64% and 26%, respectively.
|
|
|
We previously reported that classic standard cisplatin-based chemotherapy regimens cause severe myelotoxicity in elderly patients aged 75 years [5]. Based on that previous study of elderly patients with NSCLC, we conducted phase I studies in which cisplatin and docetaxel were administered as three consecutive weekly infusions in both non-elderly and elderly patients with NSCLC using the same eligibility criteria, except for age, and the same definitions of dose-limiting toxicity and maximum-tolerated dose [15]. Our hypothesis was that the recommended dose for elderly patients aged
75 years would differ from that for non-elderly patients. In the previous phase I studies, we demonstrated a difference in the recommended dose of docetaxel combined with cisplatin between non-elderly and elderly patients [15]. The recommended doses of docetaxel with 25 mg/m2 cisplatin were 35 and 20 mg/m2 on days 1, 8 and 15 for non-elderly and elderly patients, respectively. We also conducted phase II studies for non-elderly and elderly patients with NSCLC using each recommended dose and the same eligibility criteria, except for age. The results of the phase II study for non-elderly patients with NSCLC have been reported elsewhere [16]. Among the 33 evaluable patients, an objective tumor response of 30% (95% CI 15% to 46%) and a median survival time of 12.8 months were observed [16]. In the current study, we observed an objective tumor response of 52% (95% CI 31% to 67%) and a median survival time of 15.8 months for elderly patients with NSCLC. In spite of the lower dose of docetaxel, the efficacy of the treatment did not seem to be diminished.
Italian oncology groups have conducted randomized trials for elderly patients aged 70 years [2123]. In these studies, non-platinum-based single or double chemotherapy regimens, such as vinorelbine alone or vinorelbine plus gemcitabine were used for elderly patients with NSCLC [2123]. These chemotherapy regimens might not be adequate for non-elderly patients with a good PS because the cisplatin plus vinorelbine regimen was significantly superior to vinorelbine alone with regard to both the response rate and the survival [24, 25]. Kubota et al. [26] reported that the frequency of grade 4 leukocytopenia in the elderly (
70 years of age) group was significantly greater than in the non-elderly group and that no difference in overall survival was observed between the two groups. Langer et al. [27] reported that advanced age alone should not preclude appropriate NSCLC treatment, although elderly patients aged
70 years have more co-morbidities and can expect a higher incidence of leukopenia and neuropsychiatric toxicity. In the United States, upper age limits are not included in eligibility criteria to avoid age discrimination. In contrast, most Japanese studies have upper age limits because Japanese government guidelines recommend that elderly patients, >75 years, should not be accrued in common clinical trials [28]. This recommendation was made in concern for the safety of elderly patients. In Japan, most clinical trials include patients aged
74 years, and the full-dose chemotherapy is administered. Clinical trials for elderly patients have generally been conducted as specific trials focusing on the treatment of elderly patients in Japan. However, the definition of elderly is still unclear. Thus, the use of platinum-based chemotherapy in elderly patients with NSCLC remains controversial because no randomized phase III studies have been conducted to resolve this question.
Several chemotherapy trials for elderly patients with NSCLC have been reported [2123, 29] (Table 5). Of the subjects in these trials, 1841% were PS 2 patients. Eligible patients were 70 or 65 years or older. The response rates of the non-platinum-based single or double chemotherapy regimens ranged from 15% to 22%, and the median survival times ranged from 18 to 36 weeks [2123, 29]. In the current study, however, PS 2 patients were excluded and only patients aged 75 years were included. The objective response rate of 52% (95% CI 31% to 67%) and the median survival time of 15.8 months (69 weeks) in our trial were extremely better than those of previous trials. We considered that the main reason for the better results was the exclusion of PS 2 patients. However, cisplatin chemotherapy might be important not only for non-elderly, but also for elderly patients with NSCLC.
|
We conclude that cisplatin and docetaxel administered as three consecutive weekly infusions is very effective and safe for elderly patients with chemotherapy-naive NSCLC. The JCOG is conducting a phase III study of cisplatin and docetaxel versus docetaxel alone, administered as three consecutive weekly infusions, for elderly patients with NSCLC to examine the role of cisplatin in the treatment of elderly patients with NSCLC.
![]() |
Acknowledgements |
---|
![]() |
FOOTNOTES |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Yamamoto S, Yamaguchi N. Cancer statistics digest; lung cancer mortality. Jpn J Clin Oncol 1998; 28: 352.[ISI]
3. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 14341441.[ISI][Medline]
4. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899909.
5. Oshita F, Kurata T, Kasai T et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 1995; 86: 11981202. [ISI][Medline]
6. Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994; 12: 12321237.[Abstract]
7. Fossella FV, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994; 12: 12381244.[Abstract]
8. Kunitoh H, Watanabe K, Onoshi T et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 1996; 14: 16491655.[Abstract]
9. Fossella FV, Lee JS, Shin DM et al. Phase II study of docetaxel (Taxotere) for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13: 645651.[Abstract]
10. Gandara DR, Vokes E, Green M et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000; 18: 131135.
11. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 9298.
12. Hainsworth JD, Burris HA III, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 21642168.[Abstract]
13. Briasoulis E, Karavasilis V, Anastasopoulos D et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999; 10: 701706.[Abstract]
14. Greco FA. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 1999; 26 (Suppl 11): 2831.
15. Ohe Y, Niho S, Kakinuma R et al. Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn J Clin Oncol 2001; 31: 100106.
16. Niho S, Ohe Y, Kakinuma R et al. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer 2002; 35: 209214.[CrossRef][ISI][Medline]
17. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207214.[ISI][Medline]
18. Tobinai K, Kohno A, Shimada Y et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250257.[ISI][Medline]
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 110.[ISI][Medline]
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457481.[ISI]
21. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 6672.
22. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362372.
23. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. a Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 2001; 34: S65S69.[CrossRef]
24. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360367.[Abstract]
25. Le Chevalier T, Brisgand D, Soria JC et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001; 6 (Suppl 1): 811.
26. Kubota K, Furuse K, Kawahara M et al. Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40: 469474.[CrossRef][ISI][Medline]
27. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173181.
28. Ohe Y, Saijo N. Results of recent Japanese clinical trials in lung cancer. Clin Lung Cancer 2002; 3: 243248.[Medline]
29. Hainsworth JD, Burris HA III, Litchy S et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network phase II trial. Cancer 2000; 89: 328333. [CrossRef][ISI][Medline]